By Josh White
Date: Friday 13 Jun 2025
(Sharecast News) - Primary Health Properties defended its £1.2bn offer for Assura on Friday, reiterating that the proposed all-share and cash deal offered strategic and financial benefits, as it urged Assura shareholders not to accept a rival bid from private equity-backed Sana Bidco.
Form 8.5 EPT/Non RI Primary Health Props Replace | 20-Jun-2025 | 17:45 | RNS |
Form 8.3 - PHP LN | 20-Jun-2025 | 15:30 | RNS |
Form 8.3 - Primary Health Properties plc | 20-Jun-2025 | 15:25 | Business Wire |
Form 8.3 - Primary Health Properties plc | 20-Jun-2025 | 15:20 | RNS |
Form 8.3 - PRIMARY HEALTH PROPERTIES PLC | 20-Jun-2025 | 14:35 | RNS |
Nine property companies poised to convert to Reits | 31-Dec-2006 | Sunday Telegraph |
Questor:Primary Health Properties | 23-Nov-2011 | Telegraph |
Questor :Primary Health Properties | 20-Apr-2011 | Telegraph |
Questor : Primary Health Properties | 08-Dec-2010 | Telegraph |
Dividends are the key to a sensible investment s... | 28-Dec-2009 | Sunday Telegraph |
Questor: Primary Health Properties | 31-Aug-2009 | Sunday Telegraph |
No recent information was found.
Currency | UK Pounds |
Share Price | 103.50p |
Change Today | 0.50p |
% Change | 0.49 % |
52 Week High | 103.60 |
52 Week Low | 86.15 |
Volume | 7,146,074 |
Shares Issued | 1,336.49m |
Market Cap | £1,383.27m |
Beta | 0.01 |
RiskGrade | 84 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 6 |
Latest | Previous | |
---|---|---|
Q3 | Q2 | |
Ex-Div | 03-Jul-25 | 27-Mar-25 |
Paid | 15-Aug-25 | 09-May-25 |
Amount | 1.77p | 1.77p |
Time | Volume / Share Price |
14:52 | 1 @ 103.40p |
14:52 | 1 @ 103.40p |
14:52 | 1 @ 103.40p |
14:52 | 1 @ 103.40p |
14:52 | 1 @ 103.40p |
CFO | Richard Howell |
CEO | Mark Davies |
You are here: research